ADVIA CENTAUR HBC TOTAL READYPACK REAGENTS AND ADVIA CENTAUR HBC TOTAL QUALITY CONTROL MATERIALS

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P040004 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the transition of the advia centaur hbc total assay to a new platform in the centaur family of instruments, the centaur cp. The device, as modified, will be marketed under the trade name advia centaur hbc total assay and is indicated for:advia centaur hbc total readypack reagents on the centaur cp analyzer:the advia centaur hbc total assay is an in vitro diagnostic test for the qualitativedetermination of total antibodies to the core antigen of the hepatitis b virus (hbc total)in human serum or plasma (potassium edta, or lithium or sodium heparinized) using the advia centaur cp system. This assay can be used as an aid in the diagnosis ofindividuals with acute or chronic hepatitis b virus (hbv) infection and in the determination of the clinical status of hbv infected individuals in conjunction with other hbv serological markers for the laboratory diagnosis of hbv disease associated with hbv infection. This assay can also be used as an aid in the differential diagnosis inindividuals displaying signs and symptoms of hepatitis in whom etiology is unknown. Advia centaur hbc total quality control materials on the centaur cp analyzer:for monitoring the performance of the hbc total assay on the advia centaur systems. The performance of the hbc total quality control material has not beenestablished with any other anti-hbc total assays.

DeviceADVIA CENTAUR HBC TOTAL READYPACK REAGENTS AND ADVIA CENTAUR HBC TOTAL QUALITY CONTROL MATERIALS
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSIEMENS HEALTHCARE DIAGNOSTICS
Date Received2008-08-26
Decision Date2009-10-20
PMAP040004
SupplementS002
Product CodeLOM
Advisory CommitteeMicrobiology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address SIEMENS HEALTHCARE DIAGNOSTICS 333 Coney Street walpole, MA 02032-1516

Supplemental Filings

Supplement NumberDateSupplement Type
P040004Original Filing
S021 2022-03-22 30-day Notice
S020 2021-04-01 30-day Notice
S019 2020-12-22 Real-time Process
S018 2020-07-31 30-day Notice
S017 2020-03-09 30-day Notice
S016 2020-02-21 30-day Notice
S015 2019-02-01 30-day Notice
S014 2018-07-19 Real-time Process
S013 2017-07-17 Normal 180 Day Track
S012 2015-07-13 Normal 180 Day Track
S011 2015-06-11 30-day Notice
S010 2014-09-09 Normal 180 Day Track
S009 2012-03-26 Normal 180 Day Track No User Fee
S008 2012-01-09 30-day Notice
S007 2010-01-08 30-day Notice
S006 2009-05-18 Normal 180 Day Track
S005 2009-03-31 Normal 180 Day Track
S004 2009-03-09 Normal 180 Day Track No User Fee
S003 2009-02-04 30-day Notice
S002 2008-08-26 Normal 180 Day Track
S001

NIH GUDID Devices

Device IDPMASupp
00630414498089 P040004 000
00630414599212 P040004 002
00630414599205 P040004 002
00630414498096 P040004 002
00630414301303 P040004 002

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.